Singapore markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
13.62-0.17 (-1.23%)
At close: 04:00PM EDT
13.62 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close13.79
Open13.82
Bid13.61 x 100
Ask13.67 x 100
Day's range13.33 - 14.18
52-week range3.94 - 17.83
Volume359,848
Avg. volume531,914
Market cap709.603M
Beta (5Y monthly)1.30
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. “We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 b

  • GlobeNewswire

    ALX Oncology Appoints Allison Dillon as Chief Business Officer

    SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer (“CBO”). “We are excited to welcome Allison to our leadership team in the midst of this promising growth period for our Company,” said Jason Lettmann, Chief Executive Officer of ALX

  • GlobeNewswire

    ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

    SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 blocker, in combination KEYTRUDA® (pembrolizumab) in patients with previously untreated and early-stage locally advanc